Other Events ·
CorMedix reports $355M cash position, reaffirms full-year revenue guidance of up to $345M
CRMDCorMedix Inc.
CorMedix Inc. announced unaudited cash and cash equivalents of approximately $355 million as of September 30, 2026. The company also reaffirmed its total revenue guidance for the full year 2026 at between $325 million and $345 million. Additionally, CorMedix provided an update on the CMS 2027 ESRD PPS final rule, noting a post-TDAPA Add-on for DefenCath of $8.32 per dialysis session for Q1 2027, which is within its previously guided range. The company anticipates the DefenCath Add-on will decline in Q2 2027 but increase in subsequent quarters, with an average rate exceeding twice the current level. CorMedix expects to discuss these results on a conference call scheduled for November 12, 2026. CorMedix is a biopharmaceutical company focused on developing and commercializing therapeutic products for institutional care settings.